Vanderbilt University Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Vanderbilt University Medical Center sits in the top decile of US sponsors by registered trial count (#51 of 15,742 sponsors by registered trial count).

677 total trials 130 currently recruiting 400 completed early-phase tilt top decile by trial count

Vanderbilt University Medical Center: 677 sponsored US clinical trials, 130 recruiting.

Vanderbilt University Medical Center sponsors 677 registered US clinical trials on ClinicalTrials.gov, 130 of them currently recruiting, and 400 completed. 70 of these trials are in Phase 3-4 (later-stage) and 127 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autonomic Failure, with 9 trials.

Top-decile sponsor footprint

Vanderbilt University Medical Center ranks in the top decile of sponsors by registered trial count (#51 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 54/100

400 of 467 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

677 total, page 14 of 14

COMPLETED

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer

NCT00675636

COMPLETED NA

Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes

NCT00399880

COMPLETED NA

Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease

NCT00388453

COMPLETED NA

Feasibility of Placing Bravo PH Capsule in Proximal Esophagus

NCT00378898

COMPLETED NA

The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation

NCT00464126

TERMINATED NA

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)

NCT00360022

COMPLETED

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988

COMPLETED Phase 2

The Activity Intervention for Chemobrain

NCT00495703

TERMINATED

Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C

NCT00525083

COMPLETED

Study of Proteins in Head and Neck Cancer Cells

NCT00896948

COMPLETED

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

NCT00899769

COMPLETED NA

The Role of the Omentum in the Treatment of Morbid Obesity

NCT00212160

COMPLETED NA

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

NCT00179127

TERMINATED

Elevated Serum HDL in Four Generations of a Nashville Family

NCT00525109

COMPLETED

Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer

NCT00482872

TERMINATED

Risk Factors for Adult-Onset Brain Tumors

NCT00592865

TERMINATED Phase 1

AMP as a Better Delivery System of Adenosine

NCT00179010

COMPLETED

Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche

NCT00581490

COMPLETED

Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

NCT00592709

COMPLETED NA

Safety of Non-delayed Weight Bearing After Total Hip Replacement With Non-Cemented Fiber Metal Taper Stem

NCT00179088

COMPLETED Phase 4

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828

COMPLETED

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

NCT00899028

COMPLETED

Biomagnetic Characterization of Gastric Dysrhythmias:Study 2

NCT00178984

COMPLETED Phase 4

Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure

NCT00223678

COMPLETED

Biomagnetic Signals of Intestinal Ischemia II

NCT00179036

COMPLETED Phase 1

The Pathophysiology of Orthostatic Hypotension

NCT00748059

COMPLETED

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114

← Previous Page 14 of 14

Phase Distribution

PhaseTrial count
Phase 1 65
Phase 2 62
Phase 3 14
Phase 4 56

What is open in the Vanderbilt University Medical Center pipeline

130 recruiting of 677 indexed (19% open); 400 completed (59%).

Phase mix: 70 late (III/IV) vs 127 early (I/II) (early-phase heavy).

Top condition: Autonomic Failure (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vanderbilt University Medical Center: open-pipeline peers nationwide

Peers matched on 677 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

Vanderbilt University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01,0002,0003,000 12%14%16%18%20%22%24% Total trials Recruiting share Vanderbilt University Medical CenterThe Cleveland ClinicUniversity of California, DavisWeill Medical College of Cornell UniversityIcahn School of Medicine at Mount SinaiCalifornia Polytechnic State University-San Luis ObispoPhoenix Children's HospitalMayo ClinicUniversity of South Carolina
Vanderbilt University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vanderbilt University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 677 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this Vanderbilt University Medical Center page

677 registered trials is a research-attention snapshot, not an endorsement of Vanderbilt University Medical Center or any single study.

  • 130 of Vanderbilt University Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Autonomic Failure is the condition Vanderbilt University Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autonomic Failure trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vanderbilt University Medical Center pipeline card: 677 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.